



Yondelis sales increased 13% Y-o-Y in the first half of 2011

- *Zeltia group invested €28 mll in R&D during the first half of the year, 12% more than the same period last year*

Madrid, 28 July 2011: Group net revenues amounted to 81.3 million euro in 1H11, 3.3% more than in the same period of 2010 (78.7 million euro).

Net sales in the Biopharmaceutical business amounted to 41.0 million euro (37.6 million euro in 1H10), a 9% increase year-on-year with Yondelis contributing 38.2 million euro in sales (33.6 million euro in 1H10).

Net sales by the consumer chemicals subsidiaries totalled 39.9 million euro, which represents a slight decline (1.8%), compared to the same period last year (40.7 million euro).

The Biotechnology segment accounted for 50% of the Group's total revenues in the first half of 2011.

R&D expenditure increased by 12% year-on-year, due in large part to the commencement of new clinical trials this year. A total of 28.6 million euro was spent on research and development in 1H11, broken down as follows: PharmaMar 17.5 million euro, Noscira 8.2 million euro (7.7 million euro in 1H10), Sylentis 1.57 million euro (2.6 million euro in 1H10) and Genómica 0.7 million euro (0.6 million euro in 1H10).

As previously announced, the group has initiated a Phase II trial in patients with breast cancer stratified on the basis of XPG expression, and has also commenced a Phase IIb trial with Nypta (tideglusib) in Alzheimer's disease. Other important events in the first half of the year include the certification of Sylentis as a pharmaceutical laboratory for the analysis of research products by the Spanish Medicines Agency, and approval for Genómica to market its CLART® products in Brazil.



About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marinebased drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a Biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

For more information, contact Zeltia at +34 91 444 4500.

This note is also available in the "News" section of Zeltia's website (www.zeltia.com) and the "Pressroom" section of Noscira's website (www.noscira.com)